TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05622890
Drug: Mirvetuximab Soravtansine
Normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Study: NCT04718714
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
Study: NCT04718714
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
Study: NCT04718714
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
Study: NCT05306249
Drug: CBD LGP 50
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
Study: NCT05718648
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1015550
Study: NCT04907279
Drug: Aripiprazole Once-Monthly (AOM)
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage and frequency of AOM administration individualized for each study participant in accordance with investigators' clinical judgment.
Study: NCT04697953
Drug: brolucizumab
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-filled Syringes for intravitreal injection
Study: NCT06155097
Drug: transversus thoracis muscle plane block (TTP)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard monitors. After determining the anterior T4-T5 interspace using US, the US probe places in the longitudinal plane 1 cm lateral to the sternal border. A parasternal sagittal view of the internal intercostal muscle and the transversus thoracis muscle between the fourth and fifth rib will be visualized above the pleura. A 22-gage needle will be inserted in plane to the transducer with the tip of the needle located in the TTP between the internal intercostal and transversus thoracis muscles. After excluding intravascular and intrapleural placement, LA will administer with intermittent aspiration (administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side. After block administration, the patients will be monitored for LA toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes.
Study: NCT06155097
Drug: parasternal intercostal nerve block (PSI block)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard. Ultrasound scan will be performed from lateral to medial in the intercostal space. The intercostal muscles and pleura will be identified along the lower border of the rib. At the lateral border of the sternum, internal thoracic vessels lying anterior to transverse thoracic muscle are identified. The needle will be inserted in-plane to follow its tip using 4-mL injections per intercostal space across levels two through six bilaterally, for a total of 40 mL (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone)
Study: NCT05853757
Drug: Zzowin Nutra Tablet
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 Tablet daily half an hour before going to bed
Study: NCT05771584
Drug: rhuGM-CSF
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 μg
Study: NCT06322147
Drug: Doublet or triplet chemotherapy combined with cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy+cetuximab combination therapy，chemotherapy regimens include FOLFOX, FOLFIRI, XELOX, or mFOLFOXIRI.~Cetuximab first dose 400 mg/m2, followed by cetuximab 250 mg/m2 every 2 weeks;~mFOLFOX6: oxaliplatin 85 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h) for up to 12 cycles;~XELOX (biweekly): oxaliplatin 85 mg/m2 (day 1), capecitabine 1000 mg/m2, bid, d1-10;~FOLFIRI: irinotecan 180 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h), Up to 12 cycles;~mFOLFOXIRI: oxaliplatin 85 mg/m2 (day 1), irinotecan 150 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1) and 5-FU 2400 mg/m2 CIV (46 h).
Study: NCT04908345
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used at induction and during surgery
Study: NCT05828836
Drug: Allopurinol Tablet
Normalized name: Allopurinol Tablets
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: allopurinol300mg once daily
Study: NCT04976647
Drug: HLX10+HLX07
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
Study: NCT04710199
Drug: Maraviroc experimental group
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300-milligram dose of the drug two times daily , oral way. During 14 days.
Study: NCT04393311
Drug: Ulinastatin
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin administered via IV infusion (200,000/infusion)
Study: NCT05281003
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
Study: NCT05281003
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Paclitaxel 150 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
Study: NCT05281003
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Cisplatin 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
Study: NCT03417921
Drug: Gemcitabine and nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gemcitabine and nab-paclitaxel as standard pattern
Study: NCT05389527
Drug: Pembrolizumab+Lenvatinib
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight \<60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year.
Study: NCT05544552
Drug: TYRA-300
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
Study: NCT04990778
Drug: Eprenetapopt
Normalized name: Eprenetapopt
DrugBank: Eprenetapopt (DB11684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04990778
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04853615
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PAtient will receive empagliflozin 25 mg daily
Study: NCT05774899
Drug: CB-103
Normalized name: CB-103
DrugBank: CB-103 (DB15279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-in-class pan-NOTCH inhibitor, capsule taken orally.
Study: NCT05774899
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4/6 inhibitor, tablet taken orally.
Study: NCT05774899
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Per standard care, capsule taken orally.
Study: NCT05075512
Drug: anlotinib, fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
Study: NCT05570305
Drug: Zibotentan
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 1.5 mg once per day as a hard capsule.
Study: NCT04103554
Drug: Sacubitril-Valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
Study: NCT05088967
Drug: sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg d1 IV every 3 weeks
Study: NCT05570305
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg once per day as a tablet.
Study: NCT05570305
Drug: Dapagliflozin and Zibotentan
Normalized name: metformin and dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.
Study: NCT04692467
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine, Haiti's first-line antihypertensive medication, will be administered to the intervention group.
Study: NCT05254327
Drug: BMX-001
Normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
Study: NCT00002198
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05671497
Drug: Cilostazol 100 MG
Normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antiplatelet agent used for intermittent claudication , it has an anti-inflammatory effect which will help control patients with Rheumatoid arthritis
Study: NCT05671497
Drug: conventional synthetic antirheumatic drugs
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily
Study: NCT04729205
Drug: Promitil
Normalized name: PROMITIL
DrugBank: JNJ-27548547 (DB15372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).
Study: NCT05006118
Drug: Radio-labeled rodatristat ethyl 600 mg
Normalized name: Ethyl Acetate
DrugBank: Rodatristat (DB18478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of \[12C\]-rodatristat ethyl and \[14C\]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
Study: NCT05334043
Drug: CuminUP30
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 capsules, 500 mg / capsule
Study: NCT05334043
Drug: Curcumin capsules
Normalized name: curcumin Oral Capsule
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 capsules, 450 mg / capsule
Study: NCT04916951
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral one-time dose of amoxicillin
Study: NCT04916951
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral one-time dose of cephalexin
Study: NCT05626972
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)
Study: NCT04814498
Drug: Geneva Cocktail
Normalized name: amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed sequence use of drug cocktail
Study: NCT04814498
Drug: BLD-0409
Normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed sequence use of active product
Study: NCT05999890
Drug: Tapentadol Hydrochloride
Normalized name: Tapentadol Hydrochloride
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia
Study: NCT05202990
Drug: Fecal Microbiota Transplantation by Intra-rectal enemas
Normalized name: fecal microbiota, live Enema
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas.
Study: NCT04702516
Drug: Ozempic
Normalized name: Ozempic
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
Study: NCT05200936
Drug: MM-120
Normalized name: ubidecarenone 120 MG
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.
Study: NCT03723135
Drug: CC-486
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azacitidine administered as directed by treating physician.
Study: NCT04596995
Drug: Rozanolixizumab
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period.
Study: NCT04684667
Drug: Propranolol Therapy for Infantile Hemangioma
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
Study: NCT04699968
Drug: SHR-1701，Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR -1701, Intravenous ；Famitinib, oral
Study: NCT04699968
Drug: SHR-1701
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR -1701, Intravenous
Study: NCT01419340
Drug: Torrent's Donepezil Hydrochloride Tablets 10mg
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06146777
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT05454345
Drug: Sitafloxacin
Normalized name: sitafloxacin
DrugBank: Sitafloxacin (DB13261)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: In our Intervention group, sitafloxacin replace the ethambutol, 200mg/d
Study: NCT05454345
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, Rifampin 600mg (8-12mg/kg/d)
Study: NCT05454345
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 2000mg (20-30mg/kg/d)
Study: NCT05454345
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In our Intervention group, rifapentine replace rifampin, 600mg/d
Study: NCT05454345
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 300mg (4-6mg/kg/d)
Study: NCT05454345
Drug: Ethambutol
Normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethambutol is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 1200mg (15-25mg/kg/d)
Study: NCT05454345
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin is a fourth-generation fluoroquinolone with potent activity against M. tuberculosis in vitro and in vivo, 400mg (7.5-10mg/kg/d)
Study: NCT04940364
Drug: Pozelimab
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenous (IV) or subcutaneous (SC) per protocol
Study: NCT04940364
Drug: Cemdisiran
Normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC per protocol
Study: NCT05692869
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05692869
Drug: Pseudoephedrine
Normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05492812
Drug: Chloral Hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral Hydrate
Study: NCT05570812
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (4-week ramp, 4-week steady dosing)
Study: NCT05492812
Drug: Hydroxyzine
Normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine
Study: NCT04553263
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
Study: NCT01539174
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01539174
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05515354
Drug: Nicotine Replacement Therapy Agent
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
Study: NCT06280456
Drug: Tranexamic Acid Powder
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation with different drainage clamping time.
Study: NCT00417053
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00417053
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00417053
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00417053
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00417053
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05563389
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active arm
Study: NCT05694975
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The total dosage of vitamin C for the treatment group is 24 g per day.
Study: NCT05258747
Drug: Olaparib tablets, 150 mg
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia